“We think it’s going to be a very, very difficult market environment for the next at least 18 months,” Kumar said in an interview. “The question that I hope we're all struggling with is, how do we make sure that we can continue to serve patients at scale, and which models are going to allow us to get through these inevitable, cyclical dips? And so hopefully everyone's taking notes on that.”
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,